Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials - sprookjes - yvandenbroek - TriplyDB

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials

http://www.wikidata.org/entity/Q28294225

about

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making Systematic reviews to ascertain the safety of diabetes medications Update on the treatment of type 2 diabetes mellitus Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials Clinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patients Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.Incretin-based therapies in prediabetes: Current evidence and future perspectives Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.Update on strategies limiting iatrogenic hypoglycemia.Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.Low-event-rate meta-analyses of clinical trials: implementing good practices.Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan: A Population-Based Cohort Study.Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort Study Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats.Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.Alogliptin (nesina) for adults with type-2 diabetes.The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes.Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.Antihyperglycaemic therapies and cancer risk.Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?Linagliptin: an update of its use in patients with type 2 diabetes mellitus.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Alogliptin: a review of its use in patients with type 2 diabetes mellitus.An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.Saxagliptin for the treatment of diabetes - a focus on safety.NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.New fixed dose chemical combinations: the way forward for better diabetes type II management?Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan.Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction.Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.Japanese Clinical Practice Guideline for Diabetes 2016.Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis.

P2860

Q24568148-82E278F3-3E74-4FFF-9F6B-09195DEC7E8C Q26738873-F57C4A71-A88A-44B8-9ECA-1EFBECF9303B Q26992979-B9A75892-699B-45F1-8E38-3FC7478AE5FE Q27000766-10DEEDDC-BA93-4720-BB77-1E5CB1CA3980 Q28073342-B1F680B4-30A5-43A3-ADC2-CBDD6898514A Q28081569-2593B02E-8E11-4EED-A997-602D6E150BDA Q28083144-0406A320-EE8A-4444-85E6-F81ED75EEE91 Q30848457-75D7C455-B3B5-4182-B6EF-93C418CDFBF9 Q34699191-C6C6FF5F-642C-460A-BD2F-D29D1D8A5BA6 Q34780873-F5C111D4-1E35-431A-880D-27D8B133EDD6 Q35881959-63BE856A-B09B-42E2-A5A8-D3BE36A5680D Q36064235-3CF02D2E-3BE4-41BF-8474-679242E7BB2D Q36963353-34C81A79-ADBB-4F3D-A5CC-86DAD7D2D13C Q37176363-A6EA2A3E-D10E-4702-8DBC-3703F05E95A4 Q37206067-91C9977D-3FA4-40F5-99EF-117080A6D994 Q37229615-8017CD1F-628E-46D3-834B-17F2C1AAA529 Q37427294-E74C4C2E-D978-491A-AE80-385856D4EF86 Q37728819-718498B1-CB09-42B5-B536-157327345FCE Q37733244-88868DD6-AC12-4804-BC64-1266958EDB08 Q38205588-C47DE82C-E443-4792-82C9-0AFFC22F034C Q38212472-04396FD7-AF29-4623-BA1A-D1AC0F11FE10 Q38215452-718B7FBD-B249-45F0-A33C-8170D950716E Q38242089-79604D2F-1154-437A-88B7-261E68E9B89A Q38250719-F14BD2AC-329F-4728-840E-0661EA754A05 Q38255715-0A79C734-B333-43A8-AAE9-17701E676A9C Q38258278-F19CA265-13EC-435A-AA45-2B3E0EE7DF53 Q38335751-1EBC747F-A53A-4DC7-8E34-5A181D3D19BD Q38412153-13980BC1-766A-409A-8ED0-AB1F6A9BD291 Q38556037-E93A088A-D6CC-4C48-AB9E-5BBFD1217AF9 Q38645792-77DB788A-3920-4865-AE25-BD713E7855F3 Q38651175-7EA884D4-3275-4E63-BAC6-F8D9AB3993E6 Q38753500-76019AEC-8190-4C61-B857-13C570896F11 Q38778476-BB08AE9B-CD66-4D51-9B5C-B4D9C0D3B9BF Q38971792-61C3456E-B0AD-40D1-97E8-6B35EB909F75 Q40478079-596DE934-80AB-4C98-A72D-BB51728D75F2 Q40571635-1F95829C-68D3-48AD-BB0D-5849AC167E52 Q41422603-12B30FE5-CC77-4BF6-AD76-A5208439C286 Q47386188-F99ECAAA-4E73-4B8C-ABBC-28564EFCD36D Q55069710-D7FCF65C-CFCB-417F-9A98-B918F76477E8 Q55262447-8B2F6B72-6428-4363-BFC0-A727F33EA4F9

P2860

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials

http://www.wikidata.org/entity/Q28294225

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@ast

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@en

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@nl

type

label

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@ast

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@en

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@nl

prefLabel

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@ast

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@en

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@nl

P1433

Q28294225-33BFBA8F-1032-4CFD-8C6F-BF3AE88FDB6E

P1476

Q28294225-B2E5A61B-A19E-41C5-9FA3-B231B6D7012B

P2093

Q28294225-14A57F71-4486-40FB-965D-9A13CD8BDA33

Q28294225-3B1D8805-B8C1-462C-BD53-D53682AC7E0B

Q28294225-C891DFC2-4BD4-4BA7-8A56-A422055988F3

P2860

Q28294225-0457D98B-9A78-49A6-8808-21B0CAEE5510

Q28294225-0E023D60-F5F3-4040-8543-9D5B360E6C26

Q28294225-0E03CD23-AEF3-4EC2-B94D-02630B891865

Q28294225-0E1F383D-4C48-421E-964E-4F8DB1297C5E

Q28294225-0FCC5A2A-6E5A-4CA4-9F7E-0CE53C60307C

Q28294225-11004194-3741-46D4-BD5E-D3BCE135B883

Q28294225-15A04B04-BD0A-474B-BB8E-6C2429AE6A8A

Q28294225-1629F336-1356-45F8-9B93-A51356448848

Q28294225-17F78297-5099-499A-88E5-EC2F2DBDA1CC

Q28294225-19299BA4-B2DC-4C59-8646-3D5782A1B178

P304

Q28294225-842118B3-87CE-4B59-A254-5E3E04FD473F

P31

Q28294225-364790CC-A281-45B4-822F-A75CA9BA69A0

Q28294225-9A57A2B7-4F3A-4DC2-97FC-9282604C45C8

P3181

Q28294225-D01A7DD1-B466-4C2B-9C48-FF514E705775

P356

Q28294225-3BC62E7A-A89F-43C9-A742-0DB21B002BB8

P407

Q28294225-746EAD70-F3CA-42DC-9E64-66A452629D91

P433

Q28294225-5610914B-2F17-41AA-8AA9-364DD25D521D

P478

Q28294225-1CE707E5-E30B-4A1D-8B76-96CCC4D77BED

P577

Q28294225-2740D613-557E-4FB1-874E-E93BF7A8DFDB

P5875

Q28294225-16D299FF-4AE5-460B-A12A-080C9780FD7E

P698

Q28294225-64C97EE3-FFA6-4932-AF4D-A563AFFFAB14

P921

Q28294225-0DD1A7EC-B9DE-4753-A183-7726245F2398

P3181

P356

P1433

Diabetes, Obesity and Metabolism

P1476

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@en

P2093

E Mannucci

http://www.w3.org/2001/XMLSchema#string

I Dicembrini

http://www.w3.org/2001/XMLSchema#string

M Monami

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Bias in meta-analysis detected by a simple, graphical test

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Operating characteristics of a rank correlation test for publication bias

Measuring inconsistency in meta-analyses

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.

P304

48-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3423540

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/DOM.12176

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259548426

http://www.w3.org/2001/XMLSchema#string

P698

23837679

http://www.w3.org/2001/XMLSchema#string

P921